Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

Stopped early · Phase 3

Conditions studied: Normal Pressure Hydrocephalus

In brief

To determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.

Key facts

Study ID

NCT01092546

Run by

GE Healthcare

People needed

12

Starts

2010-03-01

Expected to finish

2011-04-01

Last updated by the study team

2013-12-13

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject is at least 50 years of age.
• The subjects' general health is adequate to comply with study procedures.
• The subject has been scheduled for a shunt placement procedure for the treatment of NPH.

You may not qualify if…

• The subject has a contraindication for MRI or PET.
• The subject is pregnant or lactating.
• The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol or to any of the excipients.
• The subject has participated in any clinical study using an investigational agent within 30 days of dosing.

Where it is running

• GE Healthcare — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.